Methods to modulate, to potentiate and to down-regulate a type 1 immune response in a patient, to enhance the production of a cytokine associated with a type 1 immune response, to down-regulate the production of a cytokine associated with an immune response of type 2, to stimulate production of interleukin-12 (il-12) by a macrophage, to inhibit the production of interleukin-10 (il-10) by a macrophage, to produce an immunomodulatory molecule, and to modulate a response immune in a cell, modified tumor cells, and host, biosynthetic immunomodulatory molecules, and isolated nucleic acid, expression vector, and pharmaceutical composition

摘要

"METHODS FOR MODULATING, FOR POTENTIALIZING AND FOR REGULATING A TYPE 1 RESPONSE DOWN IN A PATIENT, POPE TO ENHANCE THE PRODUCTION OF AN ASSOCIATED CYTOKINE WITH TYPE 1 IMMUNE RESPONSE, TO REGULATE DOWN THE PRODUCTION OF A ASSOCIATED TYPE OF COCTINE WITH RESPONSE 2, TO STIMULATE THE PRODUCTION OF INTERLEUCIN-12 (IL-12) BY A MACROPHAGUS, TO INHIBIT THE PRODUCTION OF INTERLEUCIN-10 (IL-10) BY A MACROPHAGUS, FOR THE PRODUCTION OF AN IMMUNOMODULATING MOLECULE, AND TO MODULATE A RESPONSE INTO A CELL, MODIFIED TUMOR CELLS, AND HOST, BIOSYNTHETIC IMMUNOMODULATING MOLECULES, AND ISOLATED NUCLEIC ACID, EXPRESSION VECTOR, AND PHARMACEUTICAL COMPOSITION ". The present invention presents new approaches to modulate immune responses. In particular, the invention features methods for modulating type 1 immune responses in a subject using Eta-1 modulators (early activation of T-1 lymphocytes) / osteopontin. Exemplary methods present methods for treating infections, immune disorders and diseases, autoimmune disorders and diseases, various immunodeficiencies and cancer. Biosynthetic immunomodulatory molecules are also provided that include functional domains derived from Eta-1 / osteopontin. Preferred biosynthetic immunomodulatory molecules include an IL-12 stimulating domain derived from Eta-1 / osteopontin or an IL-10 inhibitory domain derived from Eta-1 / osteopontin. The immunomodulatory molecules of the present invention are capable of BIASING / causing; to develop sym an immune response in a subject towards a type 1 immune response. Correspondingly, therapeutic uses are disclosed that are based on the biosynthetic immunomodulatory molecules of the present invention.